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b CPO Piedmont, University Hospital ‘‘Città della Salute e della Scienza’’, Turin, Italy
c University College London, London, UK
d World Cancer Research Fund International, London, UK
e Istituto Superiore di Sanità, Rome, Italy
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1 Members of the Scientific Secretariat and/or Chairs of Expert Working Groups (as s
2 Members of the European Code against Cancer Scientific Committee.
3 (See Appendix).
http://dx.doi.org/10.1016/j.canep.2015.05.009
1877-7821/ 2015 International Agency for Research on Cancer; Licensee ELSEVIER Ltprinciples of the 4th edition of the European Code against Cancer and
e 12 recommendations to reduce cancer risk. Among the 504.6 million
ates of the European Union (EU28), there are annually 2.64 million new
n deaths from cancer. It is estimated that this cancer burden could be
ientific knowledge on causes of cancer could be translated into successful
entive tool aimed to reduce the cancer burden by informing people how to
exposures, adopt behaviours to reduce the cancer risk, or to participate in
mmes. The Code should also form a base to guide national health policies
h permits users to download and share the article for non-commercial purposes, so
l source is properly cited. This article shall not be used or reproduced in association
ggestion that IARC endorses any specific organisation, products or services. The use
le’s original URL.
Commission; EU, European Union; HPV, human papilloma virus; HBV, hepatitis B
ternational Agency for Research on Cancer; PICOS, Population, Intervention, Control,
WG, working group; WCRF/AICR, World Cancer Research Fund/American Institute of
s Albert Thomas, 69372 Lyon Cedex 08, France. Tel.: +33 0 4 72 73 84 85.
hown in Fig. 2).
d https://creativecommons.org/licenses/by-nc-nd/3.0/igo/
in cancer prevention. The 12 recommendations are: not smoking or using other tobacco products;
avoiding second-hand smoke; being a healthy body weight; encouraging physical activity; having a
healthy diet; limiting alcohol consumption, with not drinking alcohol being better for cancer prevention;
avoiding too much exposure to ultraviolet radiation; avoiding cancer-causing agents at the workplace;
reducing exposure to high levels of radon; encouraging breastfeeding; limiting the use of hormone
replacement therapy; participating in organised vaccination programmes against hepatitis B for
newborns and human papillomavirus for girls; and participating in organised screening programmes for
bowel cancer, breast cancer, and cervical cancer.
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Cancer is the second leading cause of death in Europe [1]. For
the 28 member states of the EU (EU28) – which are Austria,
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy,
Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the
United Kingdom (UK) – with a total population of 504.6 million
inhabitants in 2012, the estimated cancer burden for 2012 was
approximately 1.43 million new cancer cases in men and
1.21 million new cancer cases in women, and 716,000 cancer
deaths in men and 561,000 cancer deaths in women, all figures
excluding non-melanoma skin cancer [2].
It has been estimated that up to half of the cancer burden is
preventable [3,4]. Successful prevention requires a combination of
individual preventive action (by avoiding or reducing harmful
exposures) and group action (when exposure is eliminated or
reduced by measures effective at the population level). For
individuals to engage in successful prevention and reduction of
their cancer risk, they need to be informed about evidence-based
actions to reduce their risk of cancer. The European Code against
Cancer is a set of recommendations providing such advice on
prevention of cancer. Its 3rd edition, published in 2003 [5] (originally
the Code was developed in 1987 and revised in 1994), lists seven
recommendations on the adoption of healthier lifestyles to improve
many aspects of general health and the prevention of many cancer
deaths; four recommendations were listed as successful interven-
tions (screening and vaccinations). With the dynamics of expanding
knowledge intrinsic in science, the European Commission mandated
the International Agency for Research on Cancer (IARC) based in
Lyon (France) to revise the 3rd edition, taking into account the most
up-to-date and best available scientific evidence on causation and
prevention of cancer. Working Groups (WGs) were established
accordingly to revise the existing recommendations or suggest
additional recommendations where new scientific evidence had
become available. A Scientific Committee of lead experts on cancer
prevention in Europe was established to review the suggestions, and
then to approve the final version.
Here, we present an overview of the principles of the European
Code against Cancer update and the definition of the target
population, the methods used by the WGs to update the evidence,
and the principles of communication to ensure the recommenda-
tions are fully understood by the target audience, namely the
European citizen. Most importantly, here we present the 4th
edition of the European Code against Cancer.
2. Principles and methods
2.1. Principles
The European Code against Cancer 4th edition was built on the
following four principles:1) Sufficient scientific evidence that following the recommenda-
tion to avoid or reduce exposure to a harmful agent, or to adopt a
healthy behaviour, or participate in screening or vaccination
activities would reduce the individual’s risk of developing
cancer or dying from cancer.
All recommendations needed to be scientifically justified,
following procedures outlined below. Importantly, the Code aims
at causes of cancer or interventions shown to reduce the risk of
developing or dying from cancer; hence, for the individual there is
a scientifically established benefit, albeit obviously acknowledging
the impossibility of totally avoiding cancer. Avoiding exposures of
possible carcinogenicity where there is scientific uncertainty is not
part of the recommendations.2) The recommendations are suitable for a broad target population.
It was ensured that recommendations be applicable to a broad
target audience. The intention was not to neglect or downplay
risks, particularly affecting vulnerable groups (e.g., smaller high-
risk groups), but it was felt that they needed preventive efforts
more focused on their particular requirements. For such situations,
however, the Code attempts to raise awareness in the general
population by providing information (see below).3) The recommendation is something individuals can do to reduce
their cancer risk.
As outlined above, successful prevention is a combination of
individual actions and policies and community actions. A
principle in the recommendations of the 4th edition of the
European Code against Cancer was to focus on risks modifiable
by the individual. The intention was not to downplay the
responsibility of health decision-makers, but to provide a tool
for people responding to the question ‘‘what can I do to reduce my
cancer risk’’.4) The recommendation can be clearly and succinctly communi-
cated to the general population.
Another principle was to avoid recommendations that would
give confusing or mixed messages to people. This is particularly the
case when an individual risk–benefit analysis is needed to assess
whether the exposure carries a benefit that may outweigh the
potential risk. An example is exposure to medical radiation. X-rays
are carcinogenic to humans; however, refusing an imaging
examination may have fatal consequences [6,7]. Also some
pharmaceuticals fall into this category [7]. Therefore, each
recommendation was phrased in a way that it: (i) can be
understood by the general population, (ii) is memorable and/or
recognisable, (iii) creates a sense that cancer can be prevented, (iv)
enhances motivation to change, and (v) can be used across Europe
as a basis for public education.
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A conceptual structure for the presentation of the European
Code against Cancer was developed and comprises three levels of
information (Fig. 1). The work was performed under the work-flow
and decision-making structure shown in Fig. 2. The six topic-
related Working Groups (WGs) dealt with smoking and other
forms of tobacco use (WG Tobacco); with diet, physical activity,
body weight and alcohol consumption (WG Nutrition); with
environmental and occupational exposures and pharmaceuticals
(WG Environment); with radiation (WG Radiation); with infec-
tions and vaccinations (WG Infections); and with cancer screening
(WG Screening). Additional WGs were established for the
literature search (Literature Group) and for communication (WG
Communication, see below).
Level I is the Code itself, which includes the 12 recommenda-
tions following the principles explained in the previous section.
The recommendations were proposed by expert WGs according to
the methodology described in the next section. The proposals
were checked and sometimes revised by the WG Communication
for clarity of the message given to a general population audience.
There were sometimes several iterations between the experts on
the topic and the experts on communication, to achieve a
consensus to be presented to the Scientific Committee. The
Scientific Committee – consisting of 14 senior cancer experts from
leading European cancer research and prevention institutions –
were provided with the list of recommendations; during two
meetings in September 2013 and February 2014 these were
discussed, and the recommendations were finally approved. In
case of lack of consensus on any recommendation, a formal voting
process had been defined for the Scientific Committee, with the
final decision based on a simple majority vote. In practice, there
was always consensus on accepting the scientific basis provided
by the WGs to justify the recommendations, but voting was
applied in some instances when two versions of phrasings were
available or whether a statement should be part of the
recommendation or provided on level II (see below). All Scientific
Committee members approved the final list of recommendations
in its totality.
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Fig. 1. Conceptual structure of the 4th edition of the European Code against Cancer; level I: r
questions and answers related to the 12 ways to reduce your cancer risk, including clarifica
as to cancer prevention in general (to the general public); level III: scientific justificationLevel II was newly introduced in the 4th edition. Like level I, its
aim was to inform the general public. Level II was developed in
question-and-answer-format, explaining and providing additional
information on the recommendations as well as cancer prevention
topics not covered in level I: for instance on carcinogenic agents
not being part of any of the recommendations of the Code for the
reason of not fulfilling all the principles outlined in the previous
section. Level II was developed by the expert WGs – both the
questions and their answers. This was then reviewed by the
Working Group on Communication and by the Scientific Commit-
tee. However, the final decisions regarding level II on what and
how to present remained the responsibility of the experts on the
topic, i.e. the respective WG. Typical questions shown on level II are
further information on exposure, messages for special target
groups, and information on practical preventive actions on how to
best follow the recommendation.
Level III is the scientific justification of the recommendations,
including the justification of each recommendation of level I and
the scientific statements made in level II. Those are the peer-
reviewed publications of the current special issue and are written
in scientific language.
2.3. Methodology
A detailed description of the methodology is provided
elsewhere [8]. In brief, for a risk factor or an intervention to be
considered as recommendation it had to comply with the
principles outlined under ‘‘Principles’’.
For confirming evidence of carcinogenicity to humans, it was
decided to use the IARC Monograph series on the Evaluation of
Carcinogenic Risks to Humans [9,10] (mainly for physical, chemical
or biological factors) and the Expert Reports and Continuous
Update Project of the World Cancer Research Fund/American
Institute of Cancer Research (WCRF/AICR) (mainly for topics
related to food, nutrition, physical activity and the prevention
of cancer) [11,12]. If the topic was not recently evaluated, or if the
WG felt that more recent scientific literature may alter this
evaluation, a systematic literature review was invoked. For this
purpose, a Literature Group was established comprising scientificecommendations on 12 ways to reduce your cancer risk (to the general public); level II:
tions, messages to specific target groups, and interventions to reduce exposure, as well
of the recommendations (to experts by means of peer-reviewed publications).
[(Fig._2)TD$FIG]
Fig. 2. Work flow and decision-making structure for the 4th edition of the European Code against Cancer; WG, Working Group; PI, principal investigator.
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literature. More details are given elsewhere [8].
For interventions, it was decided to use the IARC Handbooks of
Cancer Prevention, the World Health Organisation (WHO) position
papers, and the European Guidelines for Quality Assurance in
Cancer Screening [8], complemented by comprehensive systematic
reviews performed by the Literature Group following PICOS
methodology [13–15]. This was applied to the topics of smoking
cessation, vaccinations, and for screening. More details can be
found elsewhere [16–18].
2.4. Dissemination
In order to disseminate the messages and scientific basis of the
4th edition of the European Code against Cancer, the Code was
launched on the 14th October 2014 by the IARC in a joint press
conference with the participation of the Directorate-General for
Health and Food Safety (DG SANTE) from the European Commis-
sion (EC) and IARC representatives. The European Code against
Cancer is available on the EC and IARC websites [19,20]. Questions
and answers that provide additional information about the
recommendations and the different types of cancer they help to
prevent are also published on the IARC website [20]. The scientific
justifications for the Code are published in this issue and will be
made available to the general public on the IARC website as well. In
addition to English, the Code and the questions and answers will be
available in 22 other EU official languages.
3. Results: 12 recommendations
The 4th edition of the European Code against Cancer describes
‘‘12 ways to reduce your cancer risk’’ (Box 1). The recommenda-
tions were developed to enable and encourage individuals to
modify their own cancer risk, to address a relevant cancer burden,
and to be understandable by the general population. They coveredthe following areas: tobacco smoking and use of other forms of
tobacco; second-hand smoke; healthy body weight; physical
activity; healthy diet; alcohol consumption; ultraviolet radiation
(UVR) exposure; occupational carcinogens; high levels of radon;
breastfeeding; hormone replacement therapy (HRT); human
papilloma virus (HPV) and hepatitis B virus (HBV) vaccinations;
bowel cancer screening; breast cancer screening; and cervical
cancer screening.
3.1. Tobacco
Cigarette smoking is an established cause of cancer at multiple
anatomic sites and is the single largest preventable cause of cancer
in the EU. It is the main cause of lung cancer, responsible for eight
in ten lung cancers. On average, approximately three in ten adults
in the EU smoke. The risk of developing cancers of the lung, larynx,
pharyngeal and oral cavity, oesophagus, stomach, pancreas,
bladder and cervix decreases after quitting smoking (in comparison
to those who continue smoking). Non-smoked forms of tobacco –
varying in types and concentrations of carcinogens – are used in
the EU by a much smaller proportion of the population than
cigarettes. Smokeless tobacco users have excess risk of cancer of
the oesophagus, pancreas and oral cavity; the magnitude of excess
risk is depending on the content of carcinogens in smokeless
tobacco, which for some products is low [16].
Second-hand smoke is an established cause of lung cancer
and a possible cause of cancers of the larynx and pharynx
[16]. In the EU, the domestic environment can be a place of
frequent exposure of non-smokers to second-hand smoke. In
addition, exposure to second-hand smoke still occurs to some
degree in the work environment in several EU countries. Making
the environment smoke-free, both at home and at work places,
not only protects non-smokers from cancers caused by passive
smoking but it also reduces the amount of smoking in active
smokers [16].
Box 1. European Code [3_TD$DIFF]Against Cancer[4_TD$DIFF].
EUROPEAN CODE AGAINST CANCER
12 ways to reduce your cancer risk
1. Do not smoke. Do not use any form of tobacco
[1_TD$DIFF]2. Make your home smoke [5_TD$DIFF] free. Support smoke-free policies in your
workplace
[1_TD$DIFF]3. Take action to be a healthy body weight
[1_TD$DIFF]4. Be physically active in everyday life. Limit the time you spend sitting
[1_TD$DIFF]5. Have a healthy diet:
 [6_TD$DIFF] Eat plenty of whole grains, pulses, vegetables and fruits
[2_TD$DIFF] [7_TD$DIFF] Limit high-calorie foods (foods high in sugar or fat) and avoid sugary
drinks
[2_TD$DIFF] [8_TD$DIFF] Avoid processed meat; limit red meat and foods high in salt
[1_TD$DIFF]6. If you drink alcohol of any type, limit your intake. Not drinking alcohol is
better for cancer prevention
[1_TD$DIFF]7. Avoid too much sun, especially for children. Use sun protection. Do not
use sunbeds
[1_TD$DIFF]8. In the workplace, protect yourself against cancer-causing substances by
following health and safety instructions
[1_TD$DIFF]9. Find out if you are exposed to radiation from naturally high radon levels
in your home [9_TD$DIFF]; [10_TD$DIFF]take action to reduce high radon levels
[1_TD$DIFF] 0. For women:
 [11_TD$DIFF] Breastfeeding reduces the mother’s cancer risk. If you can, breastfeed
your baby
[2_TD$DIFF] [12_TD$DIFF] Hormone replacement therapy (HRT) increases the risk of certain
cancers[13_TD$DIFF]. [14_TD$DIFF]Limit use of HRT
[1_TD$DIFF] 1. Ensure your children take part in vaccination programmes for:
 [15_TD$DIFF] Hepatitis B (for newborns)
[2_TD$DIFF] [16_TD$DIFF] Human papillomavirus (HPV) (for girls)
[1_TD$DIFF] 2. Take part in organised cancer screening programmes for:
 [17_TD$DIFF] Bowel cancer (men and women)
[2_TD$DIFF] [18_TD$DIFF] Breast cancer (women)
[2_TD$DIFF] [19_TD$DIFF] Cervical cancer (women)
[1_TD$DIFF] he European Code [3_TD$DIFF]Against Cancer focuses on actions that individual
citizens can take to help prevent cancer. Successful cancer prevention
requires these individual actions to be supported by governmental policies
and actions.
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Imbalance between energy expenditure and energy intake
promoted by an obesogenic environment leads to excess body
fat, which increases risk of cancer at nine sites: oesophagus,
colorectum, gall bladder, pancreas, breast (postmenopausal),
endometrium, ovary, kidney, and prostate (advanced stage).
Between 4% and 38% of these cancers – depending on site and sex
– can be attributed to overweight/obesity [21].
Physical activity is a complex and multidimensional behaviour
associated with decreased risks of colon, endometrial, and breast
cancers, and less consistently with cancers of the lung, pancreas,
ovary, prostate, kidney, and stomach. A substantial proportion of
the European adult population currently fails to meet physical
activity recommendations. Recently, sedentary behaviour, associat-
ed with cancer risk through weight gain, has also emerged as a
potential independent determinant [22].
Diet influences the cancer process in several ways, both
directly and indirectly, by affecting body fatness: high intakes of
fruit and vegetables may reduce the risk of cancers of the
aerodigestive tract, and dietary fibre protects against colorectal
cancer; red and processed meats increase the risk of colorectal
cancer; diets rich in high-calorie foods (such as fatty and sugary
foods) promote excess energy intake and obesity, leading to
increased risk of cancer [23].
3.3. Alcohol
Alcohol consumption is the third leading risk factor for disease
and mortality in Europe and is a cause of cancers of the oral cavity,pharynx, larynx, oesophagus, liver, colon, rectum and female
breast, even for low and moderate alcohol intakes. It is estimated
that 10% (confidence interval (CI): 7–13%) of all cancer cases in
men and 3% (CI: 1–5%) of all cancer cases in women are attributable
to alcohol consumption. The risk of cancer increases in a dose-
dependent manner involving several biological mechanisms where
ethanol and its genotoxic metabolite, acetaldehyde, play a major
role [24].
3.4. Environment, occupation and radiation
UVR, another exposure modifiable by the individual, is the main
cause of skin cancer (including cutaneous malignant melanoma,
basal-cell carcinoma, and squamous-cell carcinoma), which is the
most common cancer in fair-skinned populations. Excessive
exposure from natural sources can be avoided by seeking shade,
using appropriate clothing, and appropriately applying sunscreens.
Exposure from artificial sources can be avoided by not using
sunbeds or other tanning devices emitting UVR. Beneficial effects
of sun or UV exposure, such as for vitamin D production, can be
achieved while still avoiding too much sun exposure and avoiding
the use of sunbeds [25].
People are exposed throughout life to a wide range of
environmental and occupational pollutants from different sources
at home, in the workplace, or in the general environment. Several
chemicals, metals, dusts, fibres, and occupations have been
established to be causally associated with an increased risk of
cancers of the lung, skin and urinary bladder, and mesothelioma,
among others. Regulations are not homogeneous across all
countries in the EU, and protective measures in the workplace
are not used consistently by all workers all of the time. Compliance
with regulations needs to be continuously monitored. A recom-
mendation to the individual is to follow safety instructions at the
workplace [26].
Radon, a radioactive gas occurring naturally at high levels in
some geographic locations, is a major source of exposure to
ionising radiation. Indoor exposure to inhalation of radon and its
decay products is an important cause of lung cancer, causing
approximately one in ten lung cancers in Europe [6]. Exposures to
radon in buildings can be reduced through a three-step process of
identifying properties with potentially elevated radon levels,
measuring radon levels, and reducing exposures by installation of
remediation systems.
3.5. Breastfeeding
Breastfeeding is associated with a dose-dependent protective
effect on breast cancer risk in both pre- and post-menopausal
women, and a modest protective effect is suggested with regard to
endometrial and ovarian cancers. Breast cancer is the most
frequent cancer in women, showing rising incidence rates in EU
countries over the past decades. Breastfeeding is also associated
with a more rapid return to pre-pregnancy weight as well as a
lower incidence of the metabolic syndrome, and it brings several
health benefits to the child [27].
3.6. Hormone replacement therapy (HRT)
Consistent evidence exists that HRT, today almost solely
prescribed as menopausal hormone therapy, is carcinogenic
to humans and induces cancers in female genital organs and
breast. The mechanisms underlying carcinogenicity include
oestrogen-receptor-mediated responses and potentially direct
genotoxicity of female hormones, hormone metabolites, or
hormonal by-products – including reactive oxygen species
[7]. Although HRT can only be obtained by prescription in most
Box 2. Guidance on the rationale behind the phrasing of each
recommendation from the European Code against Cancer, 4th
edition (given by item).
1. Do not smoke. Do not use any form of tobacco.
This specific item is intended to be a directive statement and to
leave no room for interpretation.
2. Make your home smoke-free. Support smoke-free policies
in your workplace.
The term ‘home’ covers a range of living environments. The
word ‘support’ is positive, with connotations of being helpful
and caring. This advice is intended to apply to smokers and
non-smokers and recommends they uphold and defend the
implementation of these policies.
3. Take action to be a healthy body weight.
This item recommends that people strive towards weight
control. ‘Take action’ encompasses all actions that help a
person work towards, or maintain, a healthy body weight. In
this context, ‘action’ is not recommending specific activity, but
leaving the specific actions to the reader.
4. Be physically active in everyday life. Limit the time you
spend sitting.
‘Physically active’ is an inclusive term that encompasses all
types of activity (not just specific forms of health-relevant
activity such as gym use). The term ‘everyday life’ emphasises
that this goes beyond allocating specific times to exercise and
encourages active choices across all domains.
The second part of the recommendation focuses on sedentary
time in the light of increasing evidence that it is a risk factor. We
used the term ‘sitting’ because it is a more everyday term. We
used ‘limit’ to imply that high rates of sitting should be avoided,
without suggesting that sitting should be avoided completely.
5. Have a healthy diet:
 eat plenty of whole grains, pulses, vegetables and fruits;
 limit high-calorie foods (foods high in sugar or fat) and avoid
sugary drinks;
 avoid processed meat, limit red meat and foods high in salt.
The word ‘plenty’ is used because it was considered a positive
word with connotations of contentment.
The words ‘avoid’ and ‘limit’ are chosen because they seem to
be a more ‘gentle’ form of advice, compared with ‘do not eat’
or ‘cut out/down’ – particularly as we are not expecting the
public to entirely cut these foods out of their diet; this sugges-
tion was seen as unrealistic in our public testing and was not
well received due to the more authoritarian tone.
6. If you drink alcohol of any type, limit your intake. Not
drinking alcohol is better for cancer prevention.
This includes clarification that the recommendation applies to
all types of alcohol, and uses the word ‘if’ so that the statement
does not assume that all readers drink alcohol.
As discussed for recommendation #5, the word ‘limit’ is used
first as this is a gentler way to advise about intake compared
with directive alternatives such as ‘drink less’.
The second statement raises awareness of the increased risk of
cancer resulting from consumption of any amount of alcohol,
consistent with current evidence, but not recommending total
abstinence.
7. Avoid too much sun, especially for children. Use sun pro-
tection. Do not use sunbeds.
As before, ‘avoid’ is a softer way of advising that something
should not be done than explicitly stating not to do it, and
therefore has a less authoritarian tone.
The phrases concerning sun protection and sunbeds should be
directive with no room for interpretation.
8. In the workplace, protect yourself against cancer-causing
substances by following health and safety instructions.
The word ‘protect’ refers to keeping oneself safe and acknowl-
edges that contact cannot be avoided completely.
The word ‘following’ is a softer and more positively perceived
word for advising that something be done than alternatives
such as ‘abiding by’ or ‘adhering to’.
9. Find out if you are exposed to radiation from naturally high
radon levels in your home. Take action to reduce high radon
levels.
Inclusion of the phrase ‘find out’ prompts the reader’s aware-
ness that finding out is possible.
The word ‘reduce’ is a relative term used because the extent to
which radon levels can be reduced may differ by property, area
and personal capability. Absolute terms such as ‘remove’
would not be appropriate here.
‘Home’ is an inclusive term for all types of properties in which
someone might live. House is not appropriate because it
excludes some properties (e.g. flat, apartment, etc.).
10. For women:
 breastfeeding reduces the mother’s cancer risk. If you can,
breastfeed your baby;
 hormone replacement therapy (HRT) increases the risk of
certain cancers; limit use of HRT.
‘If you can’ was included as it acknowledges some women
cannot breastfeed. Without this phrase, we found that many
readers in our test session took offence, regarding their choice
of infant feeding method as their own affair.
‘Limit’ is a softer word for advising that HRT should only be
used when necessary.
11. Ensure your children take part in vaccination programmes
for:
 hepatitis B (for newborns);
 human papillomavirus (HPV) (for girls).
We are aware that vaccination policies vary across the EU and
‘vaccination programme’ was used to avoid giving a message
that contradicts policies in place in some countries. ‘Ensure’
was chosen as a more positive way to recommend vaccination
than ‘vaccinate’.
12. Take part in organised cancer screening programmes for:
 bowel cancer (men and women);
 breast cancer (women);
 cervical cancer (women).
The word ‘organised’ clarifies that these are official regional
or national programmes and not something the individual
need necessarily seek out from commercial organisations. It
also clarifies that we are not recommending screening over
and above what is offered in each member country. Having
one line per type of screening gives equal importance to each
of them.
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order to ensure an adequate basis for discussion with their
physician on whether or not to use it.
3.7. Infections and vaccinations
Hepatitis B is a major cause of liver fibrosis, cirrhosis and cancer,
all of which can be prevented with highly effective and safe vaccines
that have been available for more than 30 years. Application of
the vaccine to all newborns is the approach recommended by the
World Health Organization (WHO) and the one applied in most
countries in the EU. Several human papillomaviruses (HPVs) are
causes of cancers of the cervix, vulva, vagina, anus, penis and
oropharynx; highly effective and safe vaccines were licensed in
2006 and used in vaccination programmes in most European
countries – aimed mainly at young adolescent girls. Other infections
– such as hepatitis C, human immunodeficiency virus (HIV) and
Helicobacter pylori – are recognised causes of cancer, and information
is provided on level II of the Code [17].
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For cancer screening the evidence demonstrates a benefit in
terms of reduced specific mortality for colorectal, breast, and
cervical cancers and of reduced incidence for cervical and
colorectal cancers. The benefit substantially outweighs the
potential harm of examining large numbers of people who may
otherwise never have or suffer from these cancers. In the EU, bowel
cancer is the third most common cancer and the second leading
cause of death due to cancer, and breast cancer is the most
common cancer and the most common cause of death due to
cancer in women. Organised screening programmes are preferable
because they provide better conditions to ensure that the EU
quality assurance guidelines are followed in order to achieve the
greatest benefit with the least harm. Screening programmes in
the EU vary with respect to the age groups invited, the interval
between invitations, and the different types of effective screening
test used [18].
3.9. Role in cancer prevention
All the recommendations are considered to be important and
associated with a relevant reduction in the cancer burden. The
greatest benefit will come from adopting all recommendations.
Although the associated cancer burden varies to some extent
across the EU28, the recommendations are relevant to the EU28 as
a whole. Therefore, there is no country-level weighting in
the recommendations, although it was acknowledged that risk
factors differ by (i) their relative risk for the individual, (ii) their
dose–response shape, and (iii) their attributable fractions.
Importantly, cigarette smoking remains the major single cause
of cancer in Europe.
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Fig. 3. Number of new cancer cases and cancer deaths for the top 15 commonest canc
GLOBOCAN.The footnote to the Code stating: ‘‘The European Code against
Cancer focuses on actions that individual citizens can take to help
prevent cancer. Successful cancer prevention requires these individual
actions to be supported by governmental policies and actions’’ is an
essential and important part of it (Box 1). It emphasises that most
cancer risk factors have to be either complementarily or
predominantly targeted at the population level with policies
and regulations, the latter in particular with regard to exposure to
environmental pollutants. There are numerous carcinogenic
chemicals in our environment, for which appropriate regulation
leads to a reduction in the cancer burden, and many are indeed
regulated in the EU [28]. A recent prominent example is air
pollution, classified as a human carcinogen in 2013 [29], and
estimated to account for just over 7% of lung cancers for ambient
air and just over 1% for household air pollution from solid fuels in
the EU [26], despite regulation being in place.
3.10. Communication of the recommendations
From a communication point of view the following were
important to have: a limited number of items, brevity and
simplicity of each message, consistent tone, everyday language,
gentle directive tone (advisory rather than merely informative),
and avoidance of fear creation. Some explanations of the wording
and phrases are given in Box 2 for each recommendation.
4. Discussion
4.1. Reducing the cancer burden in Europe
With EU28’s 504.6 million inhabitants in 2012, the estimated
2.64 million new cancer cases and 1.28 million cancer deaths (noters in the 28 member states of the European Union; estimate for 2012 by IARC
J. Schüz et al. / Cancer Epidemiology 39S (2015) S1–S10S8counting non-melanoma skin cancer) represent a major disease
burden in the European population [1]. The most common cancer
in EU28 was cancer of the female breast with 362,000 new cases in
2012, followed closely by prostate cancer with 345,000 new cases
(Fig. 3). Other cancers in the top 15 shown in Fig. 3 are colorectal
cancer, lung cancer, bladder cancer, kidney cancer, skin melanoma,
stomach cancer, pancreatic cancer, non-Hodgkin lymphoma,
cancer of the uterus, leukaemia, liver cancer, ovarian cancer, and
cancer of lip and oral cavity. When looking at cancer deaths, lung
cancer remains the largest contributor to the overall burden, with a
total of 268,000 deaths in 2012 in men and women combined. This
is particularly striking from a prevention point of view, as the main
risk factors for lung cancer have been characterised; most lung
cancers are indeed preventable, tobacco smoking accounting for
[(Fig._4)TD$FIG]
Fig. 4. Incidence and mortality of all cancers combined (excluding non-melanoma skin can
rates (ASRs) per 100,000.
Source: GLOBOCAN 2012.the by far largest proportion of lung cancers, with contributions
from other environmental factors (e.g. air pollution, radon) and
occupational exposures (such as asbestos) [4]. Colorectal cancers
accounted for 152,000 cancer deaths in EU28, followed by female
breast cancer and prostate cancer (Fig. 3). The poorest survival
among the top 15 cancers was seen for pancreatic cancer, resulting
in a total number of deaths almost as high as the number of new
cases (Fig. 3). Cancer rates differ across Europe; Fig. 4 shows the
age-standardised incidence and mortality rates for all cancers
combined (and both genders combined) for the EU28 countries,
estimated for 2012. There is some variation across the EU28, with
higher overall cancer incidence rates in some Northern and
Western European countries, while cancer mortality is highest in
Eastern Europe.cer) in the 28 EU countries, men and women combined; shown as age-standardised
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cancer burden is preventable, with successful prevention being a
combination of individual preventive action (by avoiding or
reducing harmful exposures) and group action (when exposure
is eliminated or reduced by measures effective at the population
level) [3,4]. The first type usually aims to modify individual
behaviours: for instance quitting smoking or maintaining a healthy
body weight. The second type usually relates to regulatory
frameworks, for instance establishing smoke-free environments,
implementing worker protection, urban design conducive to active
living, or developing safety standards to protect citizens from
harmful exposure to pollutants in the general environment or the
workplace. Individual and group measures may be complementary
and inter-dependent, for example by informing individuals how to
quit smoking within a supportive regulatory framework: including
tax and price policies, making access to tobacco more difficult, or
legally enforcing smoke-free environments [30–32]. Vaccination
or screening programmes have to be set up by health authorities,
but individuals have to actively participate. Some exposures,
however, are difficult to avoid by the individual alone and then
regulatory action has an essential role; an example is air pollution.
Nevertheless, each individual can contribute to overall better air
quality by, for example, avoiding unnecessary car use, thereby
contributing to a healthier environment leading to fewer cancers
on a population level.
Vaccines prevent cancer by avoiding chronic infection with
carcinogenic viruses [33,34]. Screening prevents cancer by
detection of curable pre-cancerous lesions, and reduces cancer
mortality by early detection of asymptomatic cancers in more
curable stages [35]. Vaccines and screening may target the same
cancer, as for example cancer of the uterine cervix. Early detection
is advisable only when it is scientifically established that the
benefits of mortality reduction of a specific cancer outweigh
possible harms: for example those of over-diagnosis and related
treatment [35]. The scientific evidence of efficacy of screening for a
specific cancer (reduction of mortality for curable cancers and of
incidence for preventable cancers) is a necessary but insufficient
condition for screening implementation; a favourable balance
between screening benefits and harms should exist.
The European Code against Cancer is a key prevention tool,
providing information to the individual on how to reduce their risk
of cancer. The Code should also form a base to guide national health
policies in cancer prevention, as well as calls for complementary
measures on a society level to protect the population and to assist
the individual in reducing their cancer risk.
4.2. Conclusions on the 4th edition of the European Code against
Cancer
The 4th edition of the European Code against Cancer was
developed using a rigorous scientific process. The process was
based on: (i) identification of causes of cancer and preventive
interventions using recent comprehensive authoritative sources of
scientific evidence; (ii) evaluation of the science by experts
supported by new systematic literature searches (reviews) where
necessary; (iii) advice on effective communication to the general
population; (iv) oversight by a pan-European Scientific Committee
of senior experts of leading European institutions of cancer
research and prevention.
The outcome comprises three levels of information (Fig. 1) that
are contained in an ad-hoc website [25]: (i) the European Code
against Cancer itself comprising ‘‘12 ways to reduce your cancer
risk’’; (ii) additional information, in the form of questions and
answers, on risk factors, and what individuals can do protect
themselves; (iii) the scientific justification of the recommenda-
tions published in the peer-reviewed literature.The European Code against Cancer has the potential to be scaled
up to the global level, and to be broken down by regions of the
world, using the scientific methodology that was established and
with similar presentation of outcomes.
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